Biotech firm Prime Medicine prices $175M IPO (Pending:PRME)
seekingalpha.com
news
2022-10-20 09:13:16

TolikoffPhotography 

Prime Medicine (PRME) has priced its upsized IPO of 10,294,118 shares of its common stock at a price to the public of $17/share.
Underwriters have been granted a 30-day option to purchase up to 1,544,117 additional shares at the initial public offering price less underwriting discounts and commissions.
Gross proceeds of the offering are expected to be $175M.
Shares are expected to begin trading on the Nasdaq Global Market on October 20, 2022 under the ticker symbol "PRME."
The offering is expected to close on Oct.
